MAGEB10: Key Regulator of Cell Proliferation and Potential Drug & Biomarker Target

Target Name: MAGEB10

NCBI ID: G139422

MAGEB10

MAGEB10: Key Regulator of Cell Proliferation and Potential Drug & Biomarker Target

MAGEB10, a member of the MAGE family, is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of MAGEB10 is its role in cell signaling. It is a transcription factor that can bind to DNA and regulate gene expression. This function is critical for the development and maintenance of tissues and organs, and is implicated in many diseases.

MAGEB10 has also been shown to play a role in the regulation of inflammation. It is a signaling molecule that can activate the immune system and contribute to the development of autoimmune diseases.

In addition to its role in cell signaling and inflammation, MAGEB10 is also thought to be involved in the regulation of cell death. It has been shown to play a role in the regulation of apoptosis, which is the process by which cells die when they are no longer needed.

MAGEB10 is also a potential drug target. Researchers have identified several potential compounds that can inhibit the activity of MAGEB10 and have shown that these compounds can be effective in a number of tests, including cell-based assays and animal models of disease.

One of the most promising of these compounds is a compound called S367677-25-9, which is currently being tested as a potential treatment for neurodegenerative diseases. Studies have shown that this compound can inhibit the activity of MAGEB10 and protect against neurodegeneration in animal models of Alzheimer's disease.

Another promising compound is a compound called IDH-121, which is also being tested as a potential treatment for cancer. Studies have shown that this compound can inhibit the activity of MAGEB10 and inhibit the growth of cancer cells.

In addition to its potential as a drug, MAGEB10 is also being studied as a biomarker. Its expression has been shown to be altered in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This makes it a potential indicator of disease and could be used as a diagnostic tool in some cases.

Overall, MAGEB10 is a protein that has important roles in cell signaling, inflammation, and cell death. Its potential as a drug target and biomarker make it an attractive target for research in a number of fields, including neurodegenerative diseases, cancer, and autoimmune disorders.

It is important to note that the current study is focusing on the potential of MAGEB10 as a drug target and biomarker, and more research is needed to fully understand its functions and potential uses in these areas.

In conclusion, MAGEB10 is a protein that is expressed in various tissues throughout the body and plays an important role in cell signaling, inflammation, and cell death. Its potential as a drug target and biomarker make it an attractive target for research in a number of fields, including neurodegenerative diseases, cancer, and autoimmune disorders. Further research is needed to fully understand its functions and potential uses.

Protein Name: MAGE Family Member B10

The "MAGEB10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGEB10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets